Bio-Rad Laboratories, a specialist in life science research and clinical diagnostics products, is launching the QX700 System-compatible Vericheck ddPCR Kit portfolio for critical quality control (QC) workflows in advanced cell and gene therapy development and other biopharma applications
The portfolio includes Vericheck ddPCR Mycoplasma Detection, Empty-Full Capsid, Replication Competent Lentivirus, CHO Residual DNA Quantification, and E. coli Residual DNA Quantification kits.
The kits extend Bio-Rad’s existing ddPCR platform portfolio with ready-to-use, application-focused validation kits for critical QC workflows in biopharma, including cell and gene therapy applications.
Bio-Rad’s QX700 platform enables seven-colour multiplexing and processes up to 384 reactions in two and a half hours, with minimal input volume, continuous loading capability, and easy-to-use software for streamlined data interpretation. Combining the performance of the QX700 Systems with the Vericheck Kits allows researchers to generate precise, reproducible, and faster results for product development, product safety and quality.
In advanced therapeutic development and manufacturing, QC testing is critical to ensure the safety and effectiveness of the product. Providing developers with a solution for high-priority QC testing needs, the new Vericheck Kits deliver validated workflows to improve confidence in vector characterisation and contamination detection, including replication-competent virus testing and residual host cell DNA quantification.
Stephen Kulisch, vice president of Marketing, Digital Biology Group, Bio-Rad, said, “The expansion of our range of Vericheck ddPCR Kits offers validated workflows with unmatched precision and sensitivity, combined with the power of the QX700 platform, enabling scalable, streamlined workflows and faster time to actionable results. By expanding the power of our QX700 platform through the development of this new portfolio of Vericheck Kits, Bio-Rad is continuing its commitment to support development of safer and more efficient advanced therapeutic development and manufacturing.”
